CD8A and melanoma: Inhibiting P4HA1 restores TCF1+ progenitor pools and mitochondrial fitness, enhancing both adoptive and endogenous systemic CD8+ T cell immunity, and offering a promising target to overcome immune escape in solid tumors.[61] Notably, CD8+ TILs in melanomas exhibit metabolic dysfunction, marked by impaired glycolysis and oxidative phosphorylation due to downregulated enolase 1 activity.